Drug intelligence / Profile preview

SNEC30

Development stage
Unknown
Lead developer
Arbro Pharmaceuticals
Modality
Nanoparticles → Drug Delivery Systems, Small Molecules
Administration
Oral
01

Overview

SNEC30 is a nano-formulated curcumin product developed by Arbro Pharmaceuticals in collaboration with the Defense Research & Development Organization (DRDO) and Jamia Hamdard University. It utilizes a patented Self Nano-Emulsifying Drug Delivery System (SNEDDS) technology (US Patent No. US8835509) to overcome the inherent poor aqueous solubility and low bioavailability of curcumin, a polyphenol derived from turmeric (*Curcuma longa*). Curcumin acts as a natural anti-inflammatory agent and antioxidant, primarily through the inhibition of cyclooxygenase-2 (COX-2) and the scavenging of free radicals. SNEC30 is delivered as a liquid-filled hard gelatin capsule and is indicated for a wide range of pro-inflammatory conditions, including arthritis, psoriasis, diabetes, and liver health. Notably, it has been included in DRDO's Nuclear Biological & Chemical Warfare (NBC) Emergency Kit for its radioprotective properties.

Brand names
SNEC30SNEC-30SNEC 30
Other names
Self Nano Emulsifying Curcumin 30mgnano-curcuminUS-patented nano-curcumin
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)15-LOX (Lysyl Oxidase)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on SNEC30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNEC30.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call